Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Norway

Marie Skłodowska-Curie Action · Running

HubMOL Hub Molecules of Metabolism and Signalling – Key regulators of Life

Coordinator
Universitetet I Tromsoe - Norges Arktiske Universitet, Norway
Runs
1 January 2025 to 31 December 2028
Status
Running
EU funding
€4.2m
Total cost
—
Partners
21 organisations in 8 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101168783

What the project is doing

In the project's own words, from its summary on CORDIS.

Metabolic disorders are a major burden on the European population and health care systems. Moreover, metabolic perturbations contribute substantially to other pathologies such as neurodegenerative disorders and cancer. The causes of metabolic dysregulation are manifold and lead to pathological shifts, often in response to imbalanced nutrition. Likewise, changes in metabolism affect signalling mechanisms and gene regulation, aggravating the pathology.

The mechanisms of this interdependence between metabolism and signalling are still not well understood. HubMOL will fill this knowledge gap and open new horizons by exploring the functional duality of a set of small molecules that are involved in all cellular functions - the Hub Molecules Of Life (HubMOLs) including ATP, SAM (S-adenosylmethionine) and the vitamin-derived cofactors, NAD, FAD, and CoA. They are key components of both metabolism and signalling networks and are interconnected, for example, through their participation in posttranslational protein modifications (PTMs).

The complexity of this emerging area requires interdisciplinary scientists equipped with comprehensive competences covering experimental, computational and systems biology as well as clinical medicine. Therefore, the main HubMOL goal is to provide world-class training in these areas to 16 DCs enabling them to establish fundamentally new insights into cofactor biology and lay the ground for patient-tailored vitamin supplementation concepts.

The strategic exposure of the 16 young researchers to leading European academic institutions, companies and clinical environments combined with systematic training in entrepreneurship and transferable skills will strongly improve their employability for positions in both private and public sectors. HubMOL will impact patients and society by developing therapies for metabolic and regulatory imbalances based on hub molecule biology.

Topics

Who is involved

OrganisationCityCountryRole
Universitetet I Tromsoe - Norges Arktiske UniversitetTromsoNorwayCoordinator
Universitaet InnsbruckInnsbruckAustriaParticipant
Waters Ges.m.b.H.WienAustriaAssociatedpartner
Societe Des Produits Nestle SAVeveySwitzerlandAssociatedpartner
Beilstein-Institut zur Förderung der Chemischen WissenschaftenFrankfurt Am MainGermanyAssociatedpartner
Eisbach Bio GmbHPlanegg- MartinsriedGermanyParticipant
Ludwig-Maximilians-Universitaet MuenchenPlaneggGermanyAssociatedpartner
Universitaet LeipzigLeipzigGermanyParticipant
Universitaetsklinikum EssenEssenGermanyParticipant
Kobenhavns UniversitetKobenhavnDenmarkParticipant
Ms-Omics ApsVedaekDenmarkParticipant
Fundacio Institut De Recerca Contra La Leucemia Josep CarrerasBadalonaSpainParticipant
Universitat Autonoma De BarcelonaCerdanyola Del VallesSpainAssociatedpartner
Consiglio Nazionale Delle RicercheRomaItalyParticipant
Universita Degli Studi Della Campania Luigi VanvitelliCasertaItalyAssociatedpartner
Academisch Ziekenhuis GroningenGroningenNetherlandsParticipant
Mimetas BVLeidenNetherlandsParticipant
Rijksuniversiteit GroningenGroningenNetherlandsAssociatedpartner
Kingman FilmproduksjonNorwayAssociatedpartner
Simula Research Laboratory ASOsloNorwayParticipant
Universitetet I BergenBergenNorwayParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI